How would you deal with constant itching (pruritus) in an elderly patient?

Chronic pruritus is itch lasting more than six weeks. It is one of the commonest and most under-treated complaints of old age, disturbing sleep, causing irritability, low mood, excoriation and secondary infection, and materially reducing quality of life.

Mechanism in ageing skin: epidermal barrier dysfunction – thinning of the epidermis, slower regeneration of keratinocytes and fibroblasts, and reduced function of sebaceous and sweat glands. The result is a reduced ability to maintain an emolliated barrier, so the skin cannot retain water. This produces xerosis, the single commonest cause of itch in the elderly, and is further aggravated by thyroid dysfunction and polypharmacy. Immunosenescence and neuronal ageing add further mechanisms.

Dermatological: asteatotic eczema (eczema craquelé) – xerotic skin with thin overlying scale and superficial fissures crossing in a pattern resembling a dried riverbed, from reduced intercellular lipids; seborrhoeic dermatitis (pruritic, well-demarcated yellow-red patches with greasy scale on scalp, eyebrows, nasolabial folds, ears, chest and flexures, driven by Malassezia furfur, and more prominent in stroke, epilepsy and Parkinson's disease); stasis dermatitis from venous hypertension; contact and allergic dermatitis; psoriasis; lichen simplex chronicus.

Infestation – always exclude scabies first. Nocturnal itch, burrows in finger web spaces, wrists, axillae, waist and genitalia, and multiple affected members in the household or institution. Crusted (Norwegian) scabies in the frail, bedbound or immunosuppressed presents with heavy scaling and surprisingly little itch, and is highly contagious. Also consider candidiasis, dermatophytosis, pediculosis and the prodrome of herpes zoster.

Bullous pemphigoid – the commonest autoimmune blistering disorder over the age of 60, with antibodies to BPAG1 (BP230) and BPAG2 / collagen XVII (BP180). Its presentation is polymorphic: it may appear for months as intractable pruritus, an eczematous dermatitis or urticaria before any blister forms. Classic form: symmetrical tense bullae on lower trunk and flexures with a negative Nikolsky sign (distinguishing it from pemphigus vulgaris); oral mucosa involved in up to one-third. Strongly associated with Parkinson's disease, dementia, cerebrovascular disease and epilepsy – a cardinal geriatric association.

Systemic causes: chronic kidney disease (uraemic pruritus), cholestasis and primary biliary cholangitis, thyroid dysfunction, diabetes mellitus, iron deficiency, polycythaemia vera (aquagenic itch after bathing), lymphoma – note that a generalised or refractory asteatotic eczema has been associated with underlying systemic lymphoma – other malignancy, and HIV.

Drugs – a major and reversible cause in the polypharmacy-laden older patient: opioids, statins, ACE inhibitors, amiodarone, hydrochlorothiazide, allopurinol, antibiotics, calcium-channel blockers, and DPP-4 inhibitors (gliptins), which are specifically linked to drug-induced bullous pemphigoid.

Neuropathic / neurogenic pruritus results from damage to a single nerve or group of nerves, causing itch in the skin they innervate. Notalgia paraesthetica – a hyperpigmented patch between the medial scapular borders, from damage to the T2–T6 sensory nerves. Brachioradial pruritus – itch of the dorsolateral forearms and elbows from C5–C9 compression due to cervical spine degeneration. Also post-herpetic itch and small-fibre neuropathy.

Psychogenic and perpetuating factors: anxiety, depression, delusional infestation; and the self-sustaining itch– scratch cycle, which continues long after the original trigger has gone.

Anogenital itch deserves separate mention. In women, lichen sclerosus – pale ivory-white plaques with a crinkly atrophic surface, purpura and scarring, destroying normal vulval architecture, with a 3.5–5% risk of squamous cell carcinoma; treat with clobetasol propionate 0.05% ointment, emollients, soap substitutes and irritant avoidance, and biopsy any suspicious, ulcerated or raised area. Also squamous cell hyperplasia and vulvodynia. The commonest general diseases causing vulval itch are diabetes, uraemia and liver failure; irritants include perfumed soap and washing powder.

History: duration; timing (nocturnal itch suggests scabies or cholestasis); distribution – generalised versus localised, and the "butterfly sign", where the unreachable interscapular area is spared, suggesting a systemic rather than skin cause; relation to bathing (polycythaemia); water temperature, soap and bathing frequency; occupational and contact exposures; a complete drug and supplement chart; household or institutional contacts; and red flags – weight loss, fever, night sweats, jaundice, lymphadenopathy.

Examination: inspect the whole skin including scalp, web spaces, genitalia and perianal area. Distinguish primary lesions (indicating a dermatosis) from the secondary changes of chronic scratching – linear excoriations, excoriated papulonodules (prurigo nodules), well-demarcated lichenified plaques (lichen simplex chronicus), and post-inflammatory hyperpigmentation. Examine lymph nodes, liver, spleen and thyroid; assess mood, sleep and cognition.

Investigations when no primary skin disease is evident, in Indian conventional units: haemoglobin (g/dL) and full blood count with differential (eosinophilia, polycythaemia), ESR, fasting and post-prandial glucose (mg/dL), serum creatinine (mg/dL) with eGFR, liver function tests with bilirubin (mg/dL) and alkaline phosphatase, TSH (µIU/mL), serum ferritin (ng/mL) and iron studies, serum calcium (mg/dL), LDH, chest radiograph, and HIV serology where indicated. Add skin scraping and dermoscopy for scabies mite, KOH mount for fungus; skin biopsy with direct immunofluorescence and anti-BP180 ELISA when bullous pemphigoid is suspected; and cervical spine imaging for brachioradial pruritus.

General skin care is the foundation and is frequently curative on its own. Short, lukewarm – never hot – showers; soap substitutes or syndet cleansers and moisturising soaps in place of ordinary soap and detergent; no scrubbing; emollient or ointment applied liberally within a few minutes of bathing and at least twice daily to restore the natural barrier function; urea-, lanolin- or ammonium-lactate-containing creams for marked xerosis; room humidification and avoidance of excessive room heating; cotton clothing; nails cut short. Educate the older person and the carer, since applying emollient to one's own back is often impossible.

Stop the culprit drug and rationalise polypharmacy using Beers criteria and STOPP-START. Suspect gliptins if bullous pemphigoid is in the differential.

Treat scabies presumptively if there is any doubt – permethrin 5% cream applied neck-down overnight and repeated after one week, or oral ivermectin (repeat dose at day 7–14; two or more doses with topical keratolytics for crusted scabies). Treat all household and institutional contacts simultaneously and launder linen and clothing in hot water. Warn that post-scabetic itch persists for 2–4 weeks and does not indicate treatment failure – otherwise the patient is repeatedly and unnecessarily re-treated.

Topical therapy: topical corticosteroid ointment in short courses for inflammatory dermatoses – discuss proper use explicitly, since improper prolonged use perpetuates further thinning of already atrophic skin. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) are steroid-sparing and useful on the face and flexures. Antipruritic counter-irritants: menthol, camphor, pramoxine and topical lidocaine. Topical capsaicin for localised neuropathic itch such as notalgia paraesthetica and brachioradial pruritus.

Systemic therapy: antihistamines are far less useful than commonly assumed outside urticaria, and sedating antihistamines should be avoided in older people (Beers criteria – delirium, falls, urinary retention, anticholinergic burden). Preferred agents: gabapentin or pregabalin for neuropathic and uraemic itch, dose-reduced for renal function and started low to avoid sedation and falls; SSRIs such as sertraline or paroxetine, or mirtazapine for cholestatic, paraneoplastic and nocturnal itch; naltrexone (µ-opioid antagonist) for opioid-induced and cholestatic itch; and narrow-band UVB phototherapy, which is safe and effective in the elderly, including in renal and idiopathic pruritus.

Cause-specific treatment: cholestasis – cholestyramine, rifampicin, naltrexone, and treat the obstruction. Chronic kidney disease – optimise dialysis adequacy, correct hyperphosphataemia and hyperparathyroidism, gabapentin, and difelikefalin. Stasis dermatitis – leg elevation above heart level for 30 minutes three to four times daily and compression stockings after excluding arterial disease, with topical steroid only during acute flares. Seborrhoeic dermatitis – topical azole antifungal (ketoconazole daily during a flare, then twice weekly for maintenance), ciclopirox, zinc pyrithione, selenium sulfide or tar shampoo.

Bullous pemphigoid: potent topical clobetasol for localised disease; oral corticosteroids with or without doxycycline for extensive disease. Osteoporosis and gastrointestinal ulcer prophylaxis must be given to every older patient started on oral steroids, and methotrexate must be dosed cautiously because of the natural 30% decline in glomerular filtration rate with ageing in addition to other renal insults.

Break the itch–scratch cycle and treat the person: cool compresses, wet wraps, distraction and habit-reversal training, treatment of coexisting depression and anxiety, and attention to sleep. Refer to orthopaedics or neurology in selected neurogenic cases, and to dermatology for refractory itch or when pemphigoid or malignancy is suspected.

Finally, apply the geriatric wrap-around. Social support, functional status, comorbidities, mobility and cognition all determine whether a treatment plan can actually be carried out. Pathy's makes the point squarely: even a simple intervention to treat a symptomatic lesion or dermatitis can provide relief and positively affect quality of life in the elderly patient.

Chronic prurigo / prurigo nodularis has become a treatable disease. The IFSI stepwise algorithm runs: step 1 – topical corticosteroid, topical calcineurin inhibitor and H1 antihistamine; step 2 – topical capsaicin, intralesional corticosteroid, UV therapy; step 3 – gabapentin, pregabalin or antidepressants where neuropathic features predominate, versus ciclosporin or methotrexate where inflammation predominates; step 4 – NK1-receptor antagonist, µ-opioid receptor antagonists, dupilumab, nemolizumab, and thalidomide as a last resort.

Dupilumab (anti-IL-4Rα, blocking IL-4 and IL-13) was the first systemic therapy approved for prurigo nodularis, on the phase 3 LIBERTY-PN PRIME and PRIME2 trials. Pooled week-24 data: 58.8% versus 19.0% achieved a clinically meaningful (≥4-point) improvement in itch, 46.4% versus 17.1% achieved clear or almost-clear skin, and 35.3% versus 8.9% achieved both. Benefit was independent of baseline demographics and of atopic status.

Nemolizumab, a first-in-class antibody against the interleukin-31 receptor α – IL-31 being the "itch cytokine" of neuroimmune crosstalk – was approved for prurigo nodularis in 2024 on the phase 3 OLYMPIA 2 trial, with reduction in itch and sleep disturbance as early as week 4. A 68-week Japanese phase II/III study showed benefit maintained or increased through 68 weeks with no rebound after cessation.

British Association of Dermatologists living guideline for nodular prurigo (2025): offer a licensed biologic (dupilumab or nemolizumab) to adults with moderate-to-severe disease who are candidates for systemic therapy (strong recommendation); consider thalidomide only for disease resistant to all other treatment, with counselling and informed consent; follow up at least once in the following 12 months using DLQI, HADS, GAD-7 and PHQ scores.

Chronic pruritus of unknown origin (CPUO) is now a named entity – itch beyond six weeks with cutaneous, systemic, neuropathic and psychogenic causes excluded. It is most prevalent in older adults (quoted prevalence in older populations ranges widely, up to around 30–45%), and is hypothesised to arise from age-related polarisation towards a type 2 immune response as a consequence of immunosenescence. The phase 3 LIBERTY-CPUO-CHIC Study A (2024) missed its primary itch endpoint at week 24, but showed nominally significant improvement on essentially every other itch measure (≥4-point WI-NRS response 44.4% versus 23.5% at week 12) and on itch-related quality of life. A proof-of-concept nemolizumab trial in CPUO began in 2025. The examinable message: there is still no drug licensed for CPUO.

Abrocitinib, an oral JAK1 inhibitor, 200 mg daily for 12 weeks in an open-label phase 2 study (JAMA Dermatology 2024) reduced peak pruritus NRS by 78.3% in prurigo nodularis and 53.7% in CPUO – promising, but JAK inhibitors carry cardiovascular, thrombotic, infective and malignancy warnings that are particularly weighty in an elderly, comorbid population.

Difelikefalin, a peripherally acting kappa-opioid receptor agonist, is approved for pruritus associated with chronic kidney disease in adults on haemodialysis, reflecting the role of opioid-pathway imbalance and kappa-receptor downregulation in uraemic itch. Case reports describe nemolizumab succeeding where difelikefalin has failed, supporting a shared IL-31 mechanism.

A Cochrane review of interventions for CPUO found only one eligible randomised trial in the entire literature; pragmatically, serlopitant, pregabalin or dupilumab are the options considered after first-line therapy fails.

Scabies is the single most important "do not miss" diagnosis in the itching Indian elder – particularly in old-age homes, hospitals, long-term care facilities and crowded joint families, where institutional outbreaks are common. Treat the index case and every contact simultaneously; permethrin 5% and oral ivermectin are both cheap and widely available.

Xerosis is aggravated by locally specific habits: very hot bucket baths, hard water, vigorous use of harsh detergent bar soaps and scrubbing with a loofah, and winter room heating. The culturally acceptable, cheap and effective intervention is pre-bath and post-bath application of coconut or sesame oil, or a paraffin-based emollient, with a syndet or soap substitute – often more successful than prescribing an expensive branded moisturiser.

High background prevalence of the systemic causes: diabetes mellitus, chronic kidney disease with a large and growing dialysis population, hepatobiliary disease, iron deficiency anaemia (very common in older Indian women), and thyroid disorders. A basic panel – haemoglobin g/dL, glucose mg/dL, creatinine mg/dL, LFT with bilirubin mg/dL, TSH µIU/mL, ferritin ng/mL – will identify most.

Cost realism, which examiners appreciate: dupilumab and nemolizumab are largely out-of-pocket and unaffordable for most Indian elderly, and AB-PMJAY / Ayushman Vay Vandana Card covers hospitalisation rather than chronic outpatient biologics. The practical Indian ladder therefore remains emollients and soap substitutes → treat the cause → topical steroid or calcineurin inhibitor → gabapentin or an SSRI → narrow-band UVB phototherapy, which is widely available in dermatology departments and is safe in the elderly.

Polypharmacy is prevalent and poorly documented; ask specifically about over-the-counter analgesics, ayurvedic and traditional preparations, and self-medicated steroid-antifungal combination creams, which are freely sold in India and produce steroid-modified tinea (tinea incognito) – a common and easily missed cause of persistent itch.

nemolizumab benefit from week 4, sustained to 68 weeks · ≥4-point NRS fall = clinically meaningful response · post-scabetic itch persists 2–4 weeks. Examiner traps: (i) Reaching for a sedating antihistamine – explicitly inappropriate in the elderly. (ii) Missing scabies, especially crusted scabies with minimal itch in the bedbound. (iii) Missing the pre-bullous phase of bullous pemphigoid presenting as months of "eczema" or intractable itch. (iv) Forgetting drug causes, particularly gliptins. (v) Prescribing long-term topical steroid on already-atrophic skin. (vi) Failing to give osteoporosis and ulcer prophylaxis with oral steroids. (vii) Treating the itch without asking whether the elder can physically reach their own back to apply the emollient. (viii) Claiming a licensed drug exists for CPUO. 15-second answer skeleton: Chronic itch >6 weeks → ageing barrier dysfunction makes xerosis the commonest cause → but systematically exclude scabies, bullous pemphigoid, drugs and systemic disease (SCRATCHED) → history including timing, distribution, butterfly sign, drug chart, contacts → examine whole skin, separate primary lesions from scratch-induced secondary lesions → targeted bloods in Indian units, scraping, biopsy with DIF, cervical spine imaging → management: emollients and soap substitutes as the backbone, stop the drug, treat scabies presumptively, topical steroid/TCI/capsaicin, then gabapentinoid, SSRI, naltrexone, NB-UVB → cause-specific: difelikefalin for CKD, biologics for prurigo nodularis → break the itch–scratch cycle and treat mood and sleep → 2023–25 updates: IL-31 and nemolizumab, dupilumab, BAD 2025, CPUO with no licensed drug → Indian context: scabies, oil-based emollients, cost, NB-UVB.

Chronic pruritus is itch lasting more than six weeks.

Epidermal barrier dysfunction of ageing skin makes xerosis the commonest cause of itch in the elderly.

Asteatotic eczema resembles a dried riverbed; a generalised or refractory form may signal underlying lymphoma.

Bullous pemphigoid may present as intractable pruritus or eczema for months before any blister appears.

Bullous pemphigoid has a negative Nikolsky sign and is associated with Parkinson's disease, dementia, stroke and epilepsy.

Notalgia paraesthetica: interscapular hyperpigmented patch from T2–T6 sensory nerve damage.

Brachioradial pruritus: dorsolateral forearm itch from C5–C9 cervical spine degeneration.

Crusted (Norwegian) scabies presents with heavy scaling and minimal itch in the frail or immunosuppressed.

Post-scabetic itch lasts 2–4 weeks and does not indicate treatment failure.

Sedating antihistamines are inappropriate in older adults under the Beers criteria.

Gabapentin and pregabalin are the drugs of choice for neuropathic and uraemic itch.

Difelikefalin is a peripherally acting kappa-opioid receptor agonist licensed for haemodialysis-associated pruritus.

IL-31 is the "itch cytokine"; nemolizumab blocks its receptor and was approved for prurigo nodularis in 2024.

Dupilumab was the first approved systemic therapy for prurigo nodularis (PRIME/PRIME2).

CPUO is commonest in older adults and still has no licensed treatment; dupilumab missed its primary endpoint in phase 3.

Lichen sclerosus carries a 3.5–5% risk of squamous cell carcinoma and is treated with clobetasol propionate 0.05%.

Every older patient on oral steroids for pemphigoid needs osteoporosis and gastrointestinal ulcer prophylaxis.